Department of Urology, Second Affiliated Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin, China.
PLoS One. 2013;8(3):e58170. doi: 10.1371/journal.pone.0058170. Epub 2013 Mar 5.
Accumulating evidence has suggested that Mothers against decapentaplegic homolog 7 (SMAD7) rs12953717 polymorphism might be related to cancer risk. However, epidemiologic findings have been inconsistent. We therefore performed a meta-analysis to clarify the association between the SMAD7 rs12953717 polymorphism and cancer risk.
A comprehensive search was conducted to identify all eligible studies of SMAD7 rs12953717 polymorphism and cancer risk. We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) to give a sense of the precision of the estimate. Heterogeneity, publication bias, and sensitivity analysis were also explored.
A total of 14 case-control studies, including 16928 cases and 14781 controls, were included in the present meta-analysis. The overall results showed that the variant genotypes were associated with a significantly increased risk of all cancer types (homozygote comparison, OR = 1.23, 95%CI = 1.10-1.38, P<0.01; heterozygote comparison, OR = 1.12, 95%CI = 1.02-1.22, P = 0.02; recessive model, OR = 1.17, 95%CI = 1.07-1.29, P<0.01; dominant model, OR = 1.15, 95%CI = 1.06-1.25, P<0.01; allelic model, OR = 1.12, 95%CI = 1.06-1.18, P<0.01). Further sensitivity analysis confirmed the significant association. In the subgroup analysis by ethnicity, SMAD7 rs12953717 polymorphism was significantly associated with cancer risk in both Caucasians and Asians. In the subgroup analysis by cancer types, SMAD7 rs12953717 polymorphism was significantly associated with colorectal cancer.
Our investigations demonstrate that rs12953717 polymorphism is associated with the susceptibility of cancer. Large-scale and well-designed case-control studies are necessary to validate the risk identified in the present meta-analysis.
越来越多的证据表明， Mothers against decapentaplegic homolog 7（SMAD7）rs12953717 多态性可能与癌症风险有关。然而，流行病学研究的结果并不一致。因此，我们进行了一项荟萃分析，以阐明 SMAD7 rs12953717 多态性与癌症风险之间的关系。
我们进行了全面的搜索，以确定所有关于 SMAD7 rs12953717 多态性与癌症风险的相关研究。我们使用比值比（OR）来评估关联的强度，95％置信区间（CI）来给出估计的精度。还探讨了异质性、发表偏倚和敏感性分析。
本荟萃分析共纳入了 14 项病例对照研究，包括 16928 例病例和 14781 例对照。总体结果表明，变异基因型与所有癌症类型的风险显著增加相关（同型比较，OR = 1.23，95％CI = 1.10-1.38，P<0.01；杂合比较，OR = 1.12，95％CI = 1.02-1.22，P = 0.02；隐性模型，OR = 1.17，95％CI = 1.07-1.29，P<0.01；显性模型，OR = 1.15，95％CI = 1.06-1.25，P<0.01；等位基因模型，OR = 1.12，95％CI = 1.06-1.18，P<0.01）。进一步的敏感性分析证实了这种显著的相关性。按种族亚组分析，SMAD7 rs12953717 多态性与白种人和亚洲人群的癌症风险显著相关。按癌症类型亚组分析，SMAD7 rs12953717 多态性与结直肠癌显著相关。
我们的研究表明，rs12953717 多态性与癌症易感性有关。需要进行大规模和精心设计的病例对照研究来验证本荟萃分析中确定的风险。
